搜索

159-2642-3062

服务热线(工作日:9:00-17:30)

武汉科斯坦生物科技有限公司

热搜词:燕窝酸,不饱和脂肪酸,神经酰胺,花青素,黄酮,皂苷

Wuhan Chemstan Biotechnology Co., Ltd.

武汉科斯坦生物科技有限公司

代谢组学

科研服务

抗体/蛋白

地       址:武汉市东湖新技术开发区高新大道666号,武汉

                 国家生物产业基地B、C、D区研发楼C1栋
产品销售:15926423062
技术服务:18971263062                                             
E - mail :
info@chemstan.com       
邮       编:430075

化合物单体

科斯坦生物(Chemstan)所有产品和服务仅用于科学研究,不为任何个人或者非科研性质的用途提供产品和服务。

Copyright @ 武汉科斯坦生物科技有限公司.All rights reserved

网站建设:中企动力武汉鄂ICP备19006850号-1

>
>
>
Research Grade Rituximab( 利妥昔单抗 )
浏览量:
产品名称:

Research Grade Rituximab( 利妥昔单抗 )

NO.
001
货号:
CSD00089
中文名称
利妥昔单抗
英文名词
Research Grade Rituximab
CAS号
174722-31-7
产品货号:
CSD00089
货期:
现货
价格与订购:
2480.00
数量
-
+
库存:
10
没有此类产品
产品信息
如何订购
货号(Catalog No.)icon
CSD00089
通用名INNicon
Rituximab
纯度(Purity)icon
>95%
浓度( Concentration)icon
1mg/ml
Formulationicon
PBS buffer PH7.5
Sourceicon
CHO cells
内毒素(Endotoxin level)icon
Please contact with the lab for this information.
产品描述(Description)icon
Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences 6, Label. It was originally approved by the U.S. FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL) 8, however, has now been approved for a variety of conditions Label. On November 28, 2018, the US FDA approved Truxima, the first biosimilar to Rituxan (Rituximab) 7.Rituximab is a monoclonal antibody that targets the CD20 antigen, which is expressed on the surface of pre-B and mature B-lymphocytes 1, 2, 3, Label. After binding to CD20, rituximab mediates B-cell lysis (or breakdown). The possible mechanisms of cell lysis include complement dependent cytotoxicity (CDC) and antibody dependent cell-mediated cytotoxicity (ADCC) Label.
别名(Alternative names)icon
IDEC-C2B8
靶点;物种(Specificity target name;species)icon
MS4A1[Homo sapiens]
活性研究(体外/体内研究)(Activity in vitro)icon
Complement-dependent cytotoxicity(CDC), complement-dependent cellular cytotoxicity(CDCC), antibody-dependent cytotoxicity (ADCC) as well as the induction of apoptosis have been claimed to be responsible for the efficacy of rituximab. Rituximab can induce death of malignant B cell lines in vitro. The strength of this effect varies considerably between target cell lines. Changes that have been identified in response to rituximab in vitro include inhibition of p38 mitogen-activated protein kinase, NF-κB, extracellular signal-regulated kinase 1/2 (ERK 1/2) and AKT antiapoptotic survival pathways. Rituximab is highly efficient at mediating CMC(complement dependent cytotoxicity) of various B cell lines as well as fresh malignant B cell samples. CD20-binding capacity of rituximab is dose-dependent.
种类(Species)icon
Chimeric
受体鉴定(Receptor identification)icon
IgG1-kappa
分子量(MV)icon
148000.00 Da
CASicon
174722-31-7
存储条件(Storage)icon
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Store at +4°C short term (1-2 weeks).
Store at -20 °C 12 months.
Store at -80°C long term.
Noteicon
For research use only .
未找到相应参数组,请于后台属性模板中添加
暂未实现,敬请期待
暂未实现,敬请期待
下一篇